Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 aggregate principal amount of its 6.28% Senior Notes, Series A, due June 26, 2015 (the “Series A Notes”) and (b) $145,000,000 aggregate principal amount of its 6.72% Senior Notes, Series B, due June 26, 2018 (the “Series B Notes”; the Series A Notes and the Series B Notes being hereinafter collectively referred to as the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1 or Exhibit 2, as the case may be. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (ai) $205,000,000 60,000,000 aggregate principal amount of its 6.284.70% Senior Notes, Series A, due June 26December 1, 2015 2023 (the “Series A Notes”) and (bii) $145,000,000 40,000,000 aggregate principal amount of its 6.724.93% Senior Notes, Series B, due June 26December 1, 2018 2025 (the “Series B Notes”; ” and, together with the Series A Notes Notes, as amended, restated or otherwise modified from time to time pursuant to Section 17 and the Series B Notes being hereinafter collectively referred to as the “Notes”, such term to include including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the form set out in Exhibit 1 or Exhibit 2, as Schedule 1(a) and the case may beSeries B Notes shall be substantially in the form set out in Schedule 1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references A. References to a “Schedule” or an “Exhibit” are, are references to a Schedule attached to this Agreement unless otherwise specified, . References to a Schedule or an Exhibit attached “Section” are references to a Section of this AgreementAgreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of $100,000,000 aggregate principal amount of Senior Notes consisting of (a) $205,000,000 50,000,000 aggregate principal amount of its 6.285.09% Series A Senior NotesNotes due March 22, Series A, due June 26, 2015 2029 (the “Series A Notes”) and (b) $145,000,000 50,000,000 aggregate principal amount of its 6.725.17% Series B Senior NotesNotes due March 22, Series B, due June 26, 2018 2029 (the “Series B Notes”; the ). The Series A Notes and the Series B Notes being are hereinafter collectively referred to collectively as the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Series A Notes and the Series B Notes shall be substantially in the form forms set out in Exhibit 1 or Exhibit 2Schedule 1(a) and Schedule 1(b), as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 100,000,000 aggregate principal amount of its 6.286.26% Senior Notes, Series A, due June 26August 3, 2015 2014 (the “Series A Notes”) and (b) $145,000,000 300,000,000 aggregate principal amount of its 6.726.44% Senior Notes, Series B, due June 26August 3, 2018 2017 (the “Series B Notes”; the Series A Notes and the Series B Notes being are hereinafter collectively referred to as the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1 or 1-A and Exhibit 21-B, as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize has authorized the issue and sale of (a) $205,000,000 100,000,000 aggregate principal amount of its 6.28Senior Notes consisting of (i) $50,000,000 aggregate principal amount of its 5.72% Senior Notes, Series A, due June 26September 30, 2015 2019 (the “Series A Notes”) and (bii) $145,000,000 50,000,000 aggregate principal amount of its 6.725.72% Senior Notes, Series B, due June 26March 30, 2018 2020 (the “Series B Notes”; ” and, together with the Series A Notes and the Series B Notes being hereinafter collectively referred to as Notes, the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 1313 of this Agreement). The Notes shall will be substantially in the form set out in Exhibit 1 or Exhibit 2Exhibits 1(a) and 1(b), with such changes therefrom, if any, as may be approved by you and the case may beCompany. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 250,000,000 aggregate principal amount of its 6.283.69% Senior Unsecured Notes, Series A, due June 26November 21, 2015 2018 (the “Series A Notes”) and (b) $145,000,000 250,000,000 aggregate principal amount of its 6.724.32% Senior Unsecured Notes, Series B, due June 26November 21, 2018 2023 (the “Series B Notes”; ) (the Series A Notes and the Series B Notes being hereinafter are collectively referred to as the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Series A Notes and the Series B Notes shall be substantially in the form set out in Exhibit 1 or 1(a) and Exhibit 21(b), as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 15,000,000 aggregate principal amount of its 6.283.38% Senior Notes, Series A, due June 26December 20, 2015 2020 (the “Series A Notes”) ), and (b) $145,000,000 15,000,000 aggregate principal amount of its 6.725.26% Senior Notes, Series B, due June 26December 20, 2018 2040 (the “Series B Notes”; the Series A Notes and the Series B Notes being hereinafter collectively referred to as the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Series A Notes and the Series B Notes shall be substantially in the form set out in Exhibit 1 or Exhibit 21-A and 1-B, as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (ai) $205,000,000 50,000,000 aggregate principal amount of its 6.284.57% Guaranteed Senior Unsecured Notes, Series A, due June 26January 24, 2015 2021 (the “Series A Notes”) and (bii) $145,000,000 50,000,000 aggregate principal amount of its 6.725.20% Guaranteed Senior Unsecured Notes, Series B, due June 26January 24, 2018 2021 (the “Series B Notes”; ,” and together with the Series A Notes and the Series B Notes being hereinafter collectively referred to as Notes, collectively, the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 1314). The Series A Notes and Series B Notes shall be substantially in the form set out in Exhibit 1 or Exhibit 21-A and 1-B, as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (ai) $205,000,000 50,000,000 aggregate principal amount of its 6.285.68% Senior Notes, Series A, due June 26December 7, 2015 2017 (the “Series A Notes”) and (bii) $145,000,000 25,000,000 aggregate principal amount of its 6.725.68% Senior Notes, Series B, due June 26December 7, 2018 (the “Series B Notes”; ,” and together with the Series A Notes and the Series B Notes being hereinafter Notes, are collectively referred to as the “Notes”, such term to include any such notes of either series issued in substitution therefor pursuant to Section 13). The Series A Notes and Series B Notes shall be substantially in the form set out in Exhibit 1 or 1-A and Exhibit 21-B, as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 50,000,000 aggregate principal amount of its 6.286.50% Senior Guaranteed Notes, Series A, due June 26August 7, 2015 (the “Series A Notes”) and (b) $145,000,000 50,000,000 aggregate principal amount of its 6.727.10% Senior Guaranteed Notes, Series B, due June 26August 7, 2018 2023 (the “Series B Notes”; the Series A Notes and the Series B Notes being are hereinafter collectively referred to as the “Notes”, ,” such term to include any such notes issued in substitution therefor pursuant to Section 13). The Notes shall be substantially in the form set out in Exhibit 1 or 1-A and Exhibit 21-B, as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 50,000,000 aggregate principal amount of its 6.282.71% Series A Senior NotesUnsecured Notes due July 30, Series A, due June 26, 2015 2019 (the “Series A Notes”) and (b) $145,000,000 150,000,000 aggregate principal amount of its 6.723.64% Series B Senior NotesUnsecured Notes due July 30, Series B, due June 26, 2018 2024 (the “Series B Notes”; ” and, together with the Series A Notes and the Series B Notes being hereinafter collectively referred to as Notes, collectively, the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Series A Notes and the Series B Notes shall be substantially in the form respective forms set out in Exhibit 1 or 1(a) and Exhibit 2, as the case may be1(b). Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 500,000,000 aggregate principal amount of its 6.28senior notes consisting of (a) $250,000,000 aggregate principal amount of its 3.24% Series A Senior NotesNotes due July 10, Series A, due June 26, 2015 2026 (the “Series A Notes”) and (b) $145,000,000 250,000,000 aggregate principal amount of its 6.723.45% Series B Senior NotesNotes due July 10, Series B, due June 26, 2018 2029 (the “Series B Notes”; the ). The Series A Notes and the Series B Notes being are hereinafter collectively referred to collectively as the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). .” The Series A Notes and the Series B Notes shall be substantially in the form forms set out in Exhibit 1 or Exhibit 2Schedules 1(a) and 1(b), as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” areA and, unless otherwise specified, to a Schedule or an Exhibit attached to for purposes of this Agreement, the rules of construction set forth in Section 22.4 shall govern.

Authorization of Notes. The Company will authorize the issue and sale of (ai) $205,000,000 6.23% guaranteed senior notes due August 11, 2011 in an aggregate principal amount of its 6.28% Senior Notes, Series A, due June 26, 2015 $50,000,000 (the “Series A Notes”) and (bii) $145,000,000 6.23% guaranteed senior notes due August 11, 2015 in an aggregate principal amount of its 6.72% Senior Notes, Series B, due June 26, 2018 $50,000,000 (the “Series B Notes”; the Series A Notes and the Series B Notes being hereinafter collectively referred to as and, together with the “Series A Notes”, the Notes, such term to include any such notes issued in substitution therefor pursuant to Section 1314 of this Agreement or the Other Agreements (as hereinafter defined)). The Series A Notes and the Series B Notes shall be substantially in the form set out in Exhibit 1 or 1-A and Exhibit 21-B, respectively, with such changes therefrom, if any, as may be approved by you and the case may beCompany. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references The Series of a Note refers to whether a “Schedule” Note is a Series A Note or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this AgreementSeries B Note.

Authorization of Notes. The Company will authorize the issue and sale of (a) $205,000,000 57,000,000 aggregate principal amount of its 6.287.81% Series E Senior NotesNotes due April 3, Series A, due June 26, 2015 2016 (the “Series A E Notes”) and (b) $145,000,000 43,000,000 aggregate principal amount of its 6.728.24% Series F Senior NotesNotes due April 3, Series B, due June 26, 2018 2019 (the “Series B F Notes”; ” and, together with the Series A Notes and the Series B Notes being hereinafter collectively referred to as E Notes, collectively, the “Notes”, such term to include any such notes issued in substitution therefor pursuant to Section 13). The Series E and Series F Notes shall be substantially in the form forms set out in Exhibit 1 or 1A and Exhibit 21B, as the case may berespectively. Certain capitalized and other terms used in this Agreement are defined in Schedule B; and references to a “Schedule” or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement.